Breast Cancer
18 drugs66,357 FAERS reportsMedDRA PT
GET
/api/v1/reaction/breast-cancerReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D001943
Tumors or cancer of the human BREAST.
Source: U.S. National Library of Medicine — MeSH (Breast Neoplasms)
Drugs reporting Breast Cancer (18)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Helicobacter Pylori2743%
- 2Acetylcholine3329%
- 3Aluminum Zirconium Octachlorohydrex Gly125%
- 4Medroxyprogesterone10,96321%
- 5Estrogens12,16717%
- 6Ranitidine29,41313%
- 7Dextran 40811%
- 8Methyltestosterone5511%
- 9Aluminum Zirconium Trichlorohydrex Gly17.7%
- 10Aprocitentan17.1%
- 11Estrone64.1%
- 12Tamoxifen2173.8%
- 13Exemestane7773.7%
- 14Anastrozole1,0382.9%
- 15Acetate11,6312.8%
- 16Retifanlimab12.7%
- 17Rosemary Oil11.9%
- 18Sodium Iodide171.5%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Breast Cancer Female5 shared · 0.25
- Metastases To Bone4 shared · 0.13
- Breast Cancer Metastatic3 shared · 0.11
- Obstruction2 shared · 0.11
- Sinus Disorder2 shared · 0.11
- Respiratory Disorder2 shared · 0.09
- Mental Impairment2 shared · 0.09
- Sleep Disorder Due To A General Medical Condition2 shared · 0.09
- Mental Disorder2 shared · 0.08
- Metastases To Liver2 shared · 0.08
Literature
Recent PubMed references pinned to Breast Neoplasms as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study.Breast cancer research and treatment · 2026 · LeVee A, Santos B, Wong M, et al.PMID 42207343DOI 10.1007/s10549-026-07984-8
- Stage-specific biomarkers in triple-negative breast cancer: Preliminary findings from bioinformatics approaches.Cancer biomarkers : section A of Disease markers · 2026 · Shahraki F, Meshkini A, Nazari E, et al.PMID 42206911DOI 10.1177/18758592261454886
- Implementation and Dosimetric Evaluation of a Knowledge-Based IMRT Model for Left-Sided Breast Radiotherapy with DIBH.Journal of applied clinical medical physics · 2026 · Senkesen O, Ispir EB, Aydin I, et al.PMID 42206589DOI 10.1002/acm2.70599
- Characterization of dosimetric predictors for pulmonary perfusion changes before and after hypofractionated whole-breast radiotherapy in node-negative breast cancer patients: A prospective study.Journal of applied clinical medical physics · 2026 · Allaveisi F, Esmaeilzadeh N, Derakhshan S, et al.PMID 42206571DOI 10.1002/acm2.70641
- Nanoparticle-Based Radiosensitization in Breast Cancer: A Multimodal Approach to Therapy and Immune Regulation.Biotechnology journal · 2026 · AlAbdulhadi SAS, Majeed AA, Polatova D, et al.PMID 42204960DOI 10.1002/biot.70242
- The Effect of Social Associations on Mammography Screening Disparities in Rural Communities: A County-Level Secondary Analysis.Cancer medicine · 2026 · Bernacchi V, Kumar A, Hirko K, et al.PMID 42204777DOI 10.1002/cam4.71990
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.